Editorial
The Lotus dilemma—respond to paravalvular leakage, but not answering pacemaker implantations?
Abstract
The treatment of symptomatic aortic valve stenosis has been revolutionized by transcatheter aortic valve replacement (TAVR), evolving from a last resort therapy to the standard treatment of patients at intermediate or high risk for conventional surgery (1,2).